

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 55949

Title: Gastrointestinal and Hepatobiliary Manifestations of COVID-19: A Comprehensive Review

Reviewer's code: 00070109

Position: Peer Reviewer

Academic degree: MD

Professional title: Chief Doctor, Professor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2020-04-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-11 03:52

Reviewer performed review: 2020-04-11 08:27

Review time: 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Nowadays , COVID-19 become a global pandemic. The authors discussed gastrointestinal and hepatobiliary manifestations, the concern for fecal-oral transmission and the impact of COVID-19 on underlying gastrointestinal diseases. There are some new information in this review.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 55949

Title: Gastrointestinal and Hepatobiliary Manifestations of COVID-19: A Comprehensive Review

Reviewer's code: 03261985

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Chief Doctor, Director, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2020-04-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-11 01:49

Reviewer performed review: 2020-04-12 01:09

Review time: 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

It is well-written reviews about gastrointestinal and hepatic manifestatins of COVID-19. It's important to get this kind of paper out soon, so I reviewed it in a hurry. There are only some minor points the author should. In the abstract, SARS-Co-V-2, AST, ALT, ACE2 should not be abbreviated because they are written only in once. In page 5, it is better to change title of the "Hepatobiliary manifestations" to "Hepatic manifestations" because biliary manifestaton is not reported in this section In page 8, SECURE-Cirrhosis should be abbreviated and in line 13, Americas is correct ?, not the US ?

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 55949

Title: Gastrointestinal and Hepatobiliary Manifestations of COVID-19: A Comprehensive Review

Reviewer's code: 04383168

Position: Peer Reviewer

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Canada

Author's Country/Territory: United States

Manuscript submission date: 2020-04-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-13 00:13

Reviewer performed review: 2020-04-13 02:11

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a narrative review of the gastrointestinal manifestations of SARS-CoV-2/COVID-19. This topic is obviously of great interest currently and the field is rapidly evolving. This appears to be a fairly comprehensive review of papers published to date on this topic and will therefore likely be of interest to readers. I have a few comments/questions that I think should be addressed prior to publication. These are generally minor. 1) What methods were employed to identify pertinent articles? Was a systematic review undertaken with a formal search strategy? If so, then please include these methods. (If not the case, this is still acceptable). 2) I have some concern about how the recommendations of the IOIBD group on IBD therapies are presented. For example, the authors state that it is recommended that patients who develop COVID-19 illness NOT stop medications like anti-TNF and ustekinumab. The IOIBD guideline available at [https://www.gastrojournal.org/article/S0016-5085\(20\)30465-0/pdf](https://www.gastrojournal.org/article/S0016-5085(20)30465-0/pdf) in fact recommend that anti-TNF and ustekinumab (and others) be stopped in patients who develop COVID-19 (in contrast to patients who only test positive for the virus without COVID-19 disease). Care should be taken to ensure that the recommendations from this guideline are accurately presented in this review. For example, it is recommended not only that prednisone >20 mg/day be stopped in patients with proven infection but also as a precaution to PREVENT infection. 3) There are several instances of acronyms appearing throughout the text without being spelled out (WHO, SIRS, TNF). Please spell out at first mention. 4) A description of reports of COVID-19 in patients with underlying liver disease and IBD is given. A comment on whether outcomes/mortality rates are higher in these patients compared to the general population would be very informative and of great interest to readers (i.e., how do the outcome rates in patients with underlying GI disease compare to outcomes rates (severe disease, mortality) in the

general population? The abstract states: Lastly, patients with underlying gastrointestinal diseases such as chronic liver disease and inflammatory bowel disease may at higher risk of developing more severe disease. It is difficult to make this claim without comparing outcome rates to those in the general population. 5) It is stated: Although there is anecdotal mention of a more severe course of COVID-19 in patients with concurrent gastrointestinal symptoms, no definite association has been established. Please provide a reference. 6) It is stated: it is important for clinicians to not be distracted by minimally elevated liver enzymes and focus on viral control and supportive care. What is meant by “viral control” as there are no proven antiviral therapies, as I understand it. 7) Suggest using the term “healthcare workers” or “healthcare providers” rather than caregivers. 8) Are there any guidelines or position statements on the approach to FMT during the pandemic (i.e., should elective FMT be suspended?). If so, please add a brief mention of recommendations. 9) In Figure 1, is it known that hepatic dysfunction is the cause of elevated LDH?